Hematology Research
The research activities in hematology include both clinical and laboratory research. Details of research interests of each faculty are noted in their individual pages.
Current areas of laboratory research programs include immunobiology of plasma cell diseases, and cellular and molecular biology of blood cell production and hematopoiesis. The research activities are funded by the National Institutes of Health.
Areas of clinical research interest include myeloma and related plasma cell disorders, coagulopathies and non-malignant hematology, sickle cell disease, and palliative care. Other faculty affiliated with the section also carry out basic and clinical research related to hematology. Research programs in hematologic malignancies are in close collaboration with colleagues in the Hematology Program at Yale Cancer Center.
In addition to the individual research programs of primary faculty members of the Section of Medical Oncology and Hematology, collaborative research projects are ongoing with faculty members of several other departments, such as Laboratory Medicine, Pathology, Immunobiology, and Genetics, who have common research interests.
Publications
2025
- Peer-Reviewed Original Research
Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes
Rodriguez-Sevilla J, Ganan-Gomez I, Kumar B, Thongon N, Ma F, Chien K, Kim Y, Yang H, Loghavi S, Tan R, Adema V, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Al-Atrash G, Bejar R, Banerjee P, Lynn Cha S, Montalban-Bravo G, Dougherty M, Fernandez Laurita M, Wheeler N, Jia B, Papapetrou E, Izzo F, Dueñas D, McAllen S, Gu Y, Todisco G, Ficara F, Della Porta M, Jain A, Takahashi K, Clise-Dwyer K, Halene S, Bertilaccio M, Garcia-Manero G, Daher M, Colla S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature Communications 2025, 16: 3450. PMID: 40216768, DOI: 10.1038/s41467-025-58662-0.Peer-Reviewed Original ResearchAltmetricOutcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen D, Ferreri C, Dhakal B, Dhanda D, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Gowda L, Anderson L, Pasquini M, Usmani S, Freeman C. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Advances 2025, 9: 1587-1592. PMID: 39786391, DOI: 10.1182/bloodadvances.2024014970.Peer-Reviewed Original ResearchAltmetricImetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchAltmetricConceptsMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstractsContemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-22. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.Peer-Reviewed Original ResearchAltmetricConceptsMyeloid-derived suppressor cellsAcute myeloid leukemiaMyelodysplastic syndromeSuppressor cellsTumor microenvironmentMyeloid leukemiaEffects of myeloid-derived suppressor cellsTargets myeloid-derived suppressor cellsLeukemic stem cell survivalRisk of leukemia relapseMDSC-targeted therapiesMDSC-mediated immunosuppressionBone marrow nicheStem cell survivalCytokine-mediated pathwaysLeukemia relapseMyeloid diseasesImprove patient outcomesMarrow nichePost-transplantationPreclinical modelsImmunosuppressive propertiesImmunosuppressive componentsFunctional reprogrammingImmune evasionReducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Borate U, Pugh K, Waller A, Welkie R, Huang Y, Bewersdorf J, Stahl M, DeZern A, Platzbecker U, Sekeres M, Wei A, Buckstein R, Roboz G, Savona M, Loghavi S, Hasserjian R, Fenaux P, Sallman D, Hourigan C, Della Porta M, Nimer S, Little R, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim T, Halene S, Komrokji R, Griffiths E, Greenberg P, Xu M, Xie Z, Bejar R, Sanz G, Patnaik M, Figueroa M, Carraway H, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver N, Churpek J, Majeti R, Bennett J, List A, Brunner A, Zeidan A. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood 2025, 145: 1369-1381. PMID: 40146152, DOI: 10.1182/blood.2023023717.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBarriers to clinical trial enrollmentPhase 3 trialClinical trial eligibilityClinical trial enrollmentClinical trialsEligibility criteriaTrial eligibilitySafety signalsTrial enrollmentExclusion criteriaEarly-phase trialsReal-world populationPhase of trialPatientsDrug safety signalsPosition statementAmerican Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster UniversityIn the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients
Mack P, Crawford J, Chang A, Yin A, Klein S, Shea P, Hirsch F, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee F, Mantis N, Kushi L, Weiskopf D, Merchant A, Reckamp K, Skarbinski J, Figueiredo J. In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients. Journal Of The National Cancer Institute 2025, djaf073. PMID: 40127178, DOI: 10.1093/jnci/djaf073.Peer-Reviewed Original ResearchAltmetricConceptsChanging public health landscapePublic health landscapeEnrollment of participantsSARS-CoV-2National Cancer InstituteRisk of SARS-CoV-2 infectionU.S. National Cancer InstituteNational Institute of AllergyOverall healthHealth landscapeSelf-reportCohort studyStudy designBiospecimen collectionInstitute of AllergySARS-CoV-2 infectionCancer InstituteStandard serological testsData elementsStudy immune responsesHematologic malignanciesClinicopathological dataNational InstituteCancer patientsCOVID-19Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
Olaghere J, Williams D, Farrar J, Büning H, Calhoun C, Ho T, Inamdar M, Liu D, Makani J, Nyarko K, Ruiz S, Tisdale J, McCune J, Boadi E, for the FDA R. Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence. Biomedicines 2025, 13: 758. PMID: 40149734, PMCID: PMC11940732, DOI: 10.3390/biomedicines13030758.Peer-Reviewed Original ResearchAltmetricConceptsFood and Drug AdministrationGene therapySickle cell diseaseFDA-approved therapiesCost of therapyRegulatory convergenceGates FoundationCell diseaseTherapyDrug AdministrationMiddle-income countriesGlobal health advocatesModel disorderRegulatory gapsInternational regulatory bodiesReagan-Udall FoundationRegulated industriesGenesRegulatory bodiesVenetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study
Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital M, Devillier R, Bewersdorf J, Goldberg A, Pigneux A, Vey N, Récher C, Stahl M, Bertoli S, Dumas P, Garciaz S. Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study. American Journal Of Hematology 2025, 100: 906-908. PMID: 40088036, DOI: 10.1002/ajh.27626.Peer-Reviewed Original ResearchAltmetricA plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer H, Azab M, Savona M. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology 2025, 21: 929-941. PMID: 40051275, PMCID: PMC11938952, DOI: 10.1080/14796694.2025.2468578.Peer-Reviewed Original ResearchAltmetricConceptsChronic myelomonocytic leukemiaAcute myeloid leukemiaIntravenous decitabineMyelodysplastic syndromeDEC-COral decitabineSide effectsRed blood cell transfusionPhase 3 clinical trialsMedian overall survivalTreatment-related deathsBlood cell transfusionDays of treatmentTransfusion independenceOverall survivalCell transfusionDecitabine groupMyelomonocytic leukemiaMyeloid leukemiaOral medicineDecitabineQuality of lifeReceiving treatmentTaking treatmentCedazuridineIntegrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population
Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsGenomic dataEstimates of mutation ratesSomatic missense mutationsGenomic informationPopulation-level estimatesCancer patient populationMissense mutationsNon-epidemiologicallyCancer patientsMutation ratePathogenic mutationsCysteine residuesCancer epidemiologyMutation-specificMutation abundanceDrug targetsMutationsIntegrates epidemiologyAbundancePatient populationEpidemiologyGenomePopulationTargeted therapyResiduesBeyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced Cytopenias
Browning S, Lourdes M, Neparidze N, Robinson T. Beyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced Cytopenias. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: 1039-1041. PMID: 39988417, DOI: 10.1016/j.ijrobp.2024.11.100.Peer-Reviewed Original ResearchAdvancing drug development in myelodysplastic syndromes
Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationEnd pointsStem cell malignanciesTime-to-event end pointsStem cell transplantationUS Food and Drug AdministrationTreatment of patientsFood and Drug AdministrationClinical trial designDrug developmentMyelodysplastic syndromeCell transplantationCurative therapyRisk stratificationPoor prognosisCell malignancyTransformative therapiesDrug AdministrationBiomarker developmentResponse definitionsTrial designFunctional assessmentTherapyPatientsClinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, de Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellstrom-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT. Blood 2025 PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAltmetricConceptsAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic Scoring SystemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsUS Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025 PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.Peer-Reviewed Original ResearchAltmetricConceptsHematopoietic cell transplantationT-cell therapyCAR-T cell therapyCAR-TCell transplantationGeriatric assessmentCellular therapyChimeric antigen T-cell therapyAmerican Society for TransplantationPromote risk stratificationAllo-HCTRisk stratificationCell therapyOlder patientsRoutine GAOlder adultsGa uptakeTherapyPhysician practice patternsTransplantationPractice patternsClinical support staffCross-sectional surveyPhysician membersDomain of GAKLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection
Fagerberg E, Attanasio J, Dien C, Singh J, Kessler E, Abdullah L, Shen J, Hunt B, Connolly K, De Brouwer E, He J, Iyer N, Buck J, Borr E, Damo M, Foster G, Giles J, Huang Y, Tsang J, Krishnaswamy S, Cui W, Joshi N. KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection. Science 2025, 387: eadn2337. PMID: 39946463, DOI: 10.1126/science.adn2337.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD8 T cellsT cellsCD8 T cell exhaustionNaive CD8 T cellsAcute LCMV infectionT cell exhaustionT cell fate decisionsLineage fidelityLCMV infectionEffector differentiationAcute infectionExhaustion programTranscription factorsImmune responseEpigenetic modulationSuppress differentiationProgenitor stateKLF2InfectionFunctional stateFate decisionsCD8Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shimony S, Stahl M, Stone R. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal Of Hematology 2025, 100: 860-891. PMID: 39936576, PMCID: PMC11966364, DOI: 10.1002/ajh.27625.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaTherapeutic management of acute myeloid leukemiaManagement of acute myeloid leukemiaEuropean Leukemia NetworkStem cell cancerTherapeutic decision-makingImmature leukemia cellsExtra-medullary tissuesMRD findingsPrognostic factorsCell cancerTherapeutic algorithmRisk classification algorithmApproved therapiesMyeloid leukemiaResponse assessmentRisk stratificationBone marrowTherapeutic managementMonitoring of disease statusPathophysiological understandingDisease characteristicsMolecular findingsTherapeutic approachesDisease statusRandomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia
Pyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu J, Jonas B, Schimmer A, Grant S, Zeidan A, Hildebrandt G, Lowrey C, Mattison R, Palmisiano N, Salhotra A, Tzachanis D, Baer M, Lin T, Patel P, Chen H, Stadler W, Odenike O, Larson R, Gajewski T, Hourigan C, Stock W, Liu H. Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Advances 2025 PMID: 39928953, DOI: 10.1182/bloodadvances.2024015176.Peer-Reviewed Original ResearchAltmetricConceptsRandomized phase II studyProgression-free survivalPhase II studyNivolumab armAdverse eventsObservation armOverall survivalII studyMedian duration of follow-upProgression-free survival curvesDuration of follow-upEfficacy of nivolumabIncomplete hematologic recoverySingle-agent nivolumabEvaluation of adverse eventsAcute myeloid leukemiaIncreased AEsAML chemotherapyMedian OSNivolumab administrationNivolumab maintenanceHematologic recoveryDisease relapseOpen-labelMedian durationAsciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAcute leukemiaPhiladelphia chromosome-positive acute leukemiaRecommended phase 2 dosePh+ acute lymphoblastic leukemiaHematopoietic stem cell transplantationDe novo ALLHematologic remission rateLymphoid blast crisisMaximum tolerated doseStem cell transplantationPhase 1 studyChronic myeloid leukemiaMulticolor flow cytometryAcute lymphoblastic leukemiaVaso-occlusive eventsCytogenetic remissionBlast crisisSymptomatic pancreatitisTolerated doseRemission ratePh+ ALLCell transplantationMedian ageEnzyme elevationLymphoblastic leukemiaSelinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, . Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. Future Oncology 2025, 21: 807-813. PMID: 39911057, PMCID: PMC11916360, DOI: 10.1080/14796694.2025.2461393.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsJAK inhibitorsNo dose limiting toxicitiesDose-limiting toxicityAbsolute mean changeSpleen volume reductionPlacebo-controlled studyBaseline to weekTreatment of patientsDose expansionDose escalationLimiting toxicitiesDouble-blindPrimary endpointPhase 3 study designXPO1 inhibitorsMean changeRuxolitinibPatientsSelinexorVolume reductionDosePhase 3InhibitorsJAKMyelofibrosisA Slow Reveal
Browning S, Dhaliwal G, Dill A, Khandakar B, Sofair A. A Slow Reveal. Journal Of General Internal Medicine 2025, 1-6. PMID: 39900872, DOI: 10.1007/s11606-025-09373-1.Peer-Reviewed Original ResearchInsights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatmentOutcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchConceptsAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian follow-upSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experienceLong-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Transplantation And Cellular Therapy 2025, 31: s404-s405. DOI: 10.1016/j.jtct.2025.01.623.Peer-Reviewed Original ResearchConceptsAnti-myeloma therapyLenalidomide-refractory multiple myelomaMedian follow-upCilta-celProgressive diseaseMultiple myelomaStandard of careFollow-upCiltacabtagene autoleucelProgression-free survivalYears of follow-upKaplan-Meier methodCox proportional hazards modelsWorsening of symptomsProportional hazards modelPatient-reported outcomesEuropean Organization for ResearchOverall survivalProlonged survivalImmunomodulatory agentsSOC armGlobal health status/quality of lifeAnchor-based approachClinical trialsLong-term benefits